文献速递湿疹皮炎与荨麻疹

特应性皮炎临床试验的估计目标:关于伴发事件重要性的专家意见

Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-02-25

针对特应性皮炎(AD)临床试验缺乏标准化分析指南的问题,本文探讨如何将国际人用药品技术要求协调理事会(ICH)关于估计目标的指导应用于AD试验设计与分析。作者提出应在AD试验中早期定义并使用估计目标,以使结果更贴近临床实践、便于跨试验比较并帮助治疗选择。

要点

  • 伴发事件指治疗开始后发生、影响测量解读或存在的事件,AD试验中常见如因剧烈瘙痒和睡眠剥夺使用补救治疗。
  • AD复发不可预测,伴发事件在试验中频繁出现,但各试验处理方式不一致,限制结果解读。
  • 作者提出AD试验应使用估计目标并在试验设计早期定义。

核心结论

  • 作者提出估计目标应用于AD试验并在试验设计早期定义,可使临床医生获得的干预试验结果更反映临床实践、便于跨临床试验比较并更有信息量以改善患者治疗选择。

研究设计与样本

  • 本文为综述,探讨ICH关于估计目标使用的指导如何应用于支持AD临床试验设计与分析。

主要发现

  • 伴发事件定义为治疗开始后发生、影响与所关注临床问题相关的测量的解读或存在的事件。
  • 由于AD复发且不可预测,伴发事件在AD试验中频繁发生,例如因剧烈瘙痒和睡眠剥夺使用补救治疗。
  • 尽管伴发事件在AD中有影响,但各试验处理方式常不一致,限制了结果解读。
  • 估计目标框架越来越多用于在考虑伴发事件的同时估计治疗效果。

临床怎么用

  • 作者提出估计目标用于AD试验并在试验设计早期定义。
  • 作者认为使用估计目标可为临床医生提供更反映临床实践的干预试验结果、帮助促进跨临床试验比较并更有信息量以改善患者治疗选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the emergence of novel targeted treatments for atopic dermatitis (AD), there is a lack of guidelines on standardizing analysis of clinical trial data. To define and estimate meaningful treatment comparisons, several factors, including intercurrent events, must be taken into account. Intercurrent events are defined as events occurring after treatment initiation that affect either the interpretation or existence of the measurements associated with clinical questions of interest. Due to the relapsing, unpredictable nature of AD, intercurrent events frequently occur in AD trials, such as use of rescue therapy for intense itch and sleep deprivation. Despite the impact of intercurrent events in AD, they are often handled in an inconsistent manner across trials, which limits results interpretation. The estimand framework is increasingly used to estimate treatment effects while accounting for intercurrent events. This review explores how guidance from the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) on the use of estimands can be applied to support AD clinical trial design and analysis. We propose that estimands are used in AD trials and defined early during trial design. The use of estimands can provide clinicians with interventional trial results that are more reflective of clinical practice, help facilitate comparisons across clinical trials, and are more informative to enable improved treatment selection for patients.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Bissonnette R, Eichenfield LF, Simpson E, et al. Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events. J Eur Acad Dermatol Venereol. 2023. PMID: 36652273. doi:10.1111/jdv.18881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。